Legal entity
All 1 tracked stories fall under one category: ip-patent. Of the tracked stories, 1 of 1 also mention ANVISA, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: ip-patent. Of the tracked stories, 1 of 1 also mention ANVISA, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6.3. We currently track 1 Legal story that mention Recce Pharmaceuticals Ltd, all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 56 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Recce Pharmaceuticals Ltd. Shared-story counts are live from our verified record — not editorial picks.
Brazil Patent Grant
Recce Pharmaceuticals officially receives patent grant from the Brazilian National Institute of Industrial Property (INPI).
Clinical Expansion
Recce expands Phase II clinical trials for RECCE® 327 in topical and intravenous applications.
US Patent Milestone
Recce secures key composition of matter patents in the United States, strengthening its North American position.
Recce Pharmaceuticals has been granted a critical patent in Brazil for its synthetic anti-infective platform, marking a significant expansion into South America's largest healthcare market. The patent protects the composition and manufacturing of its lead candidates, RECCE® 327 and RECCE® 529, as the company targets the global antimicrobial resistance crisis.
Source: proactiveinvestors.com · finance.yahoo.com
Recce Pharmaceuticals Ltd is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
